SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 67 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $77,000 | -29.4% | 14,200 | -2.7% | 0.00% | -33.3% |
Q1 2021 | $109,000 | -29.2% | 14,600 | +2.8% | 0.00% | -25.0% |
Q4 2020 | $154,000 | +20.3% | 14,200 | -2.1% | 0.00% | -33.3% |
Q3 2020 | $128,000 | -15.2% | 14,500 | +2.1% | 0.01% | -25.0% |
Q2 2020 | $151,000 | +1272.7% | 14,200 | +1094.3% | 0.01% | +700.0% |
Q2 2019 | $11,000 | +37.5% | 1,189 | +58.5% | 0.00% | 0.0% |
Q2 2018 | $8,000 | +60.0% | 750 | +53.1% | 0.00% | – |
Q4 2017 | $5,000 | -54.5% | 490 | -34.7% | 0.00% | -100.0% |
Q3 2017 | $11,000 | -42.1% | 750 | -37.8% | 0.00% | -50.0% |
Q2 2017 | $19,000 | – | 1,205 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |